Pegcetacoplan inhibits C3 activation by binding to C3 and its activation fragment C3b, thereby reducing C3 glomerular fragment deposition in patients with C3G and primary IC-MPGN.

Adjunctive corticosteroids not superior to placebo, while adjunctive corneal cross-linking associated with increased scar size.

Sepiapterin is a PAH activator that reduces blood Phe levels by increasing the intracellular concentrations of tetrahydrobiopterin and protecting against PAH enzyme misfolding.

Rezpegaldesleukin targets the interleukin-2 receptor complex in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells.

Shipments of Elevidys for nonambulatory DMD patients remain suspended while the Company evaluates an enhanced immunosuppressive regimen for these patients.

The Affordable Care Act requires insurance plans to cover services that receive an A or B grade from the task force.

The study results “highlight how even well-intentioned efforts to save patients’ time may face barriers,” the researchers wrote.

The Food and Drug Administration (FDA) has extended the review period for elinzanetant, an investigational hormone-free therapy for the treatment of moderate to severe vasomotor symptoms (VMS) due to ...

Lonapegsomatropin is a pegylated prodrug of the human growth hormone, somatropin, administered as a subcutaneous injection once-weekly.

Ateganosine is an investigational telomere-targeting therapy designed to break down telomere structure and function in cancer cells like NSCLC.

Following publication of advisories, reports of local anesthetic poisoning decreased, but reports of lidocaine poisoning and mortality increased.

Delgocitinib is a JAK inhibitor that blocks the activation of the JAK-STAT pathway which has been shown to play a key role in ...